W
ith each breathless announcement and triumphant press release, it seems clear that the Food and Drug Administration is approving new drugs at a record pace under Dr. Scott Gottlieb.
But we wanted to put that appearance to the test. So we gathered more than five years of approval data from Evaluate Pharma, covering more than 200 first-time drug approvals. And it turns out, the FDA has actually been reliably speedy under multiple administrations, consistently OK’ing drugs ahead of schedule.
Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!
SUBSCRIBE TODAYWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
Numbers are high but more than 50% are re-lables. That is not new approvals. Who is kidding who.